Compare Mesoblast Limited (MESO) vs United States Natural Gas Fund (UNG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs United States Natural Gas Fund — how do they compare? Mesoblast Limited trades at $16.08 (market cap $2.17B), while United States Natural Gas Fund trades at $10.45. The key difference: Mesoblast Limited is trading nearer its 52-week high, United States Natural Gas Fund nearer its low. Which is the better fit depends on your goals.
| MESO | UNG | |
|---|---|---|
Market Cap | $2.17B | — |
Sector | Technology | Commodities - Energy |
52-Week High | $20.96 | $16.90 |
52-Week Low | $12.88 | $10.15 |
Enterprise Value | $2.17B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $16.63, down 3.98% on the day, with a bullish technical outlook supported by moving averages. The company shows strong revenue growth with Ryoncil generating $115 million in annual revenue, though it remains unprofitable with a net loss of $102 million. Recent developments include positive Phase 3 trial progress and FDA BLA filings for new treatments.
Investment outlook balances promising pipeline progress against significant financial losses. The stock offers growth potential through commercial expansion but carries substantial risk from continued cash burn and regulatory hurdles. Analyst consensus leans bullish with 45% buy ratings, reflecting optimism about the company's transition to commercial-stage operations.
UNG trades at $10.29, down 2.09% in the last session, with technical indicators signaling a bearish trend. The stock shows oversold conditions on short-term RSI readings but faces strong selling pressure from moving averages. Recent news highlights volatility in natural gas futures, with prices influenced by weather forecasts and LNG demand fluctuations. Fundamental data is unavailable, limiting traditional valuation analysis.
The outlook remains cautious due to commodity price dependency and lack of fundamental metrics. Risks include energy market volatility and competition from equity-based natural gas ETFs. Analyst sentiment is mixed, with technicals leaning bearish but potential for short-term rebounds if gas prices stabilize.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About United States Natural Gas Fund
UNG is a commodity ETF that tracks the daily price movements of natural gas futures. It primarily invests in front-month contracts at the Henry Hub, making it a highly volatile tool for short-term trading rather than long-term holding due to contango and roll costs.
Read more on UNG →
